首页> 外文期刊>Endoscopy International Open >Efficacy of argon plasma coagulation in the management of portal hypertensive gastropathy
【24h】

Efficacy of argon plasma coagulation in the management of portal hypertensive gastropathy

机译:氩气血浆凝结治疗门脉高压性胃病的疗效

获取原文
           

摘要

Objectives: Evaluation of the outcome and experience in 2 years of management of portal hypertensive gastropathy (PHG) by argon plasma coagulation (APC) in a cohort of Egyptian cirrhotic patients. Methods: This study was conducted over a 2-year period from January 2011 to February 2013. Upper gastrointestinal endoscopy was performed to evaluate the degree and site of PHG. APC was applied to areas with mucosal vascular lesions. Results: In total, 200 cirrhotic patients were enrolled; 12 patients were excluded due to death (n?=?6) caused by hepatic encephalopathy (n?=?3), hepatorenal syndrome (n?=?2), or chronic lymphatic leukemia (n?=?1), or did not complete the treatment sessions (n?=?6), so 188 patients completed the study. PHG was mainly fundic in 73 patients (38.8?%), corporeal in 66 patients (35.1?%), and pangastric in 49 patients (26.1?%) (P?=?0.026). Patients were exposed to APC and received proton pump inhibitors together with propranolol at a dose sufficient to reduce the heart rate by 25?% or down to 55?beats/min. The mean (±?standard deviation) number of sessions was 1.65?±?0.8; six patients needed four sessions (3.2?%), 19 patients needed three sessions (10.1?%), 74 patients needed two sessions (39.4?%), and 89 patients needed one session (47.3?%). Patients with fundic and corporeal PHG required the lowest number of sessions (P?=?0.000). Patients were followed up every 2 months for up to 1 year; the end point was a complete response with improved anemia and blood transfusion requirement which was achieved after one session in 89 patients (75.4?%), two sessions in 24 patients (20.3?%) and three sessions in five patients (4.3?%). A complete response was more prevalent in patients with corporeal and fundic PHG (P?=?0.04). Conclusions: After 2 years’ experience in managing PHG, we found that a combination of APC and non-selective beta blockers was highly efficacious and safe in controlling bleeding from PHG. In addition, APC alone is rapid, and effective in the control of PHG induced bleeding, especially when beta blockers are contraindicated.
机译:目的:评估一组埃及肝硬化患者通过氩气血浆凝结(APC)治疗门脉高压性胃病(PHG)2年的结果和经验。方法:本研究从2011年1月至2013年2月进行了2年。进行上消化道内镜检查以评估PHG的程度和部位。 APC适用于有粘膜血管病变的区域。结果:总共有200名肝硬化患者入组;由于肝性脑病(n = 3),肝肾综合征(n = 2)或慢性淋巴白血病(n = 1)导致的死亡(n = 6)或死亡,排除了12例患者。未完成治疗(n?=?6),因此188名患者完成了研究。 PHG主要是胃底炎,其中73例(38.8%),66例(35.1%)以及胃癌49例(26.1%)(P = 0.026)。患者接触APC并接受质子泵抑制剂和普萘洛尔,其剂量足以使心率降低25%或降至55次/分钟。疗程的平均数(±标准差)为1.65±0.8。 6例患者需要4个疗程(3.2 %%),19例患者需要3个疗程(10.1 %%),74例患者需要2个疗程(39.4 %%),89例患者需要1个疗程(47.3 %%)。患有眼底和体表性PHG的患者需要最少的疗程(P?=?0.000)。每2个月对患者进行随访,长达1年;终点是完全缓解并改善了贫血和输血需求,在89例患者中进行了一次会议(75.4%),在24例患者中进行了两次会议(20.3%),在5例患者中进行了三次会议(4.3%) 。患有体液和眼底PHG的患者中,完全缓解更为普遍(P = 0.04)。结论:在2年的PHG管理经验之后,我们发现APC和非选择性β受体阻滞剂的组合在控制PHG出血方面非常有效且安全。此外,单独使用APC是快速的,可有效控制PHG引起的出血,尤其是当禁用β受体阻滞剂时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号